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Abstract
Introduction: Mitochondrial function influences T cell dynamics and is affected by mitochondrial DNA (mtDNA) variation.
We previously reported an association between African mtDNA haplogroup L2 and less robust CD4 cell recovery on
antiretroviral therapy (ART) in non-Hispanic black ACTG 384 subjects. We explored whether additional T cell parameters in
this cohort differed by mtDNA haplogroup.
Methods: ACTG 384 randomized ART-naı ¨ve subjects to two different nucleoside regimens with efavirenz, nelfinavir, or both.
CD4 and CD8 memory and activation markers were available at baseline and week 48 on most subjects. mtDNA sequencing
was performed on whole blood DNA, and haplogroups were determined. We studied non-Hispanic black subjects with HIV
RNA ,400 copies/mL at week 48. Analyses included Wilcoxon ranksum test and linear regression.
Results: Data from 104 subjects were included. Major African mtDNA haplogroups included L1 (N=25), L2 (N=31), and L3
(N=32). Baseline age, HIV RNA, and CD4 cells did not differ between L2 and non-L2 haplogroups. Compared to non-L2
haplogroups, L2 subjects had lower baseline activated CD4 cells (median 12% vs. 17%; p=0.03) and tended toward lower
activated CD8 cells (41% vs. 47%; p=0.06). At 48 weeks of ART, L2 subjects had smaller decreases in activated CD4 cells
(24% vs. 211%; p=0.01), and smaller CD4 cell increases (+95 vs. +178; p=0.002). In models adjusting for baseline age, CD4
cells, HIV RNA, and naı ¨ve-to-memory CD4 cell ratio, haplogroup L2 was associated with lower baseline (p=0.04) and 48-
week change in (p=0.01) activated CD4 cells.
Conclusions: Among ART-naı ¨ve non-Hispanic blacks, mtDNA haplogroup L2 was associated with baseline and 48-week
change in T cell activation, and poorer CD4 cell recovery. These data suggest mtDNA variation may influence CD4 T cell
dynamics by modulating T cell activation. Further study is needed to replicate these associations and identify mechanisms.
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The CD4
+ T-lymphocyte is the primary cellular target of HIV,
and the absolute CD4
+ T lymphocyte count is a reliable
determinant of disease progression and opportunistic infection
risk among HIV-infected persons. The CD4 count is also a major
factor in the decision to initiate antiretroviral therapy (ART) in
asymptomatic HIV-infected individuals [1]. After initiating ART,
there is substantial interindividual variability in the rate and
magnitude of CD4 recovery [2]. Many ART-treated patients (as
many as 30%) fail to attain substantial increases in CD4 count [2–
3], and poorer CD4 count responses on ART are associated with
disease progression despite adequate virologic responses [2,4].
Host genetic variation appears to play a role in CD4 count
recovery. Studies have suggested possible associations between
CD4 count recovery on ART and single nucleotide polymor-
phisms (SNPs) in chemokine receptor [5–6], human leukocyte
antigen [7–8], cytokine [9], and apoptosis-related [10] genes.
These results highlight the possibility that an important host factor
that influences HIV-infected CD4 cell turnover is regulation of
apoptosis [11–12].
T cell activation is a highly energy-dependent process that is
a hallmark of chronic HIV-1 infection and is a predictor of CD4 T
cell recovery on ART [13–17]. T cell activation is associated with
cellular apoptosis [18–20] and can be attenuated with ART, but
not completely or to the same degree in all persons [21–22]. Given
that mitochondria play critical roles in energy production,
oxidative stress, and apoptosis, their importance in cellular
immune responses and T cell turnover seems apparent. Indeed,
the importance of mitochondria-mediated, intrinsic apoptotic
pathways in normal T cell homeostasis [23–24], and in
dysregulated CD4 T cell recovery during HIV-1 infection [25]
have been described. Other investigations have identified associ-
ations between T cell activation and apoptosis that influence CD4
T cell depletion during HIV-1 infection and are improved by
ART [26–28].
Within mtDNA, combinations of SNPs allow for categorization
of individuals into haplogroups [29]. Haplogroups and other
mtDNA variants have been associated with differences in
mitochondrial function [30–31], and the clinical relevance of
haplogroups- and mtDNA variation in general- for disease risk is
well described [32–35], Few studies have examined mitochondrial
DNA (mtDNA) in T cell subsets in HIV-1-infected subjects in the
absence of ART toxicity. One described decreased mtDNA
quantity in activated (CD8.CD4) T cells compared with non-
activated subsets from HIV-1 seroconverters [36]. In another
recent study, loss of mtDNA that correlated with activation was
seen in CD8 T cells of HIV-1-infected, ART-naı ¨ve subjects [37].
With respect to genotypic mtDNA variation, a study from the
Multicenter AIDS Cohort Study (MACS) recently reported that
mtDNA variants were associated with progression to AIDS and/or
death in untreated, HIV-1-infected Caucasians [38]. We previ-
ously reported associations between several mtDNA SNPs- and
with the major African mtDNA haplogroup L2 defined by several
of these SNPs- and magnitude of CD4 T cell recovery after ART
initiation in non-Hispanic black participants in AIDS Clinical
Trials Group (ACTG) study 384 [39]. It is plausible that functional
variation in mtDNA would influence T cell dynamics such as
apoptosis in response to environmental stressors (e.g. HIV
infection and/or ART). We hypothesized that among individuals
with control of HIV replication following initiation of ART,
mtDNA variation would influence CD4 count recovery through
mechanisms that modulate the efficiency of CD4 cell proliferation,
one of these being T cell activation. In ACTG 384, persistent T
cell activation was associated with impaired CD4 recovery [17].
To more fully characterize relationships between mitochondrial
genomics, T cell activation, and CD4 count recovery, we utilized
mtDNA sequence data and comprehensive immunologic data
from a subset of ACTG 384 participants.
Methods
Ethics Statement
All ACTG 384 sites obtained local institutional review board
(IRB) approval, and all study subjects provided written, informed
consent. The ACTG Human DNA Repository (HDR) protocol
(A5128) underwent separate IRB review at each ACTG site, and
subjects provided separate written, informed consent for inclusion
of samples in the HDR. The Vanderbilt Committee for the
Protection of Human Subjects and the ACTG approved the use of
de-identified genetic and clinical data used in these analyses.
Study Population
ACTG 384 (NCT00000919) was a multicenter, double-blind,
prospective randomized clinical trial comparing the efficacy of
ART regimens consisting of three or four drugs in antiretroviral-
naı ¨ve adults [40–41]. Participants were randomized to one of six
treatment arms consisting of either didanosine and stavudine or
zidovudine and lamivudine combined with either efavirenz,
nelfinavir of both. A secondary end point of ACTG 384 was
change in CD4 cell count from baseline over 48, 96 and
144 weeks. A subset of individuals underwent comprehensive
immunologic assessments including proportions of memory
(CD45RO+/CD45RA2) and naı ¨ve (CD45RA+/CD62L+) CD4
cells and activated (CD38+/HLA-DR+) T cells by flow cytometry
[17]. Baseline characteristics for the subjects undergoing compre-
hensive immunologic assessments were not different than the
overall study population, with the exception of inclusion of fewer
Hispanic individuals [17]. For the current study, absolute CD4
counts and immunologic T cell assessments at baseline and week
48 from self-reported non-Hispanic black ACTG 384 participants
who consented to provide DNA to the ACTG HDR [42] were
analyzed. Individuals with HIV-1 RNA $400 copies/mL at week
48 were excluded from analyses. Previous publications have
reported results from genetic association analysis in the ACTG
384 cohort, and demonstrated no significant differences between
ACTG participants who provided DNA as part of the HDR and
those who did not [43–45].
Mitochondrial DNA Isolation and Sequencing
DNA was isolated from study participants using PUREGENE
(Gentra Systems Inc., Minneapolis, MN, USA). Full mtDNA
sequencing was performed using the GeneChip Human Mito-
chondrial Resequencing Array v2.0 (Affymetrix, Inc., Santa Clara,
CA, USA) [46]. Mitochondrial DNA variants were defined by
comparison with the revised Cambridge Reference Sequence
(rCRS) [47]. Haplogroups were assigned using Herrnstadt
classification [48], and collapsed into higher branch haplogroups
for analyses.
Statistical Analysis
The primary outcome of interest was change in percentage
CD4 cell activation at week 48. Additional outcomes of interest
included baseline and 48 week changes in other CD4 cell
immunologic parameters, and CD8 cell counts and activation.
Baseline parameters were compared by haplogroups using
Wilcoxon ranksum, Fisher’s exact, or chi-squared tests as
appropriate. Wilcoxon ranksum test was used to compare
mtDNA Variation and T Cell Activation in HIV
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logroups. Multivariate linear regression was used to assess
associations between mtDNA haplogroups and CD4 cell activa-
tion adjusting for baseline age, absolute CD4 count, HIV RNA,
and naı ¨ve-to-memory CD4 cell ratio. In the primary and
immunologic analyses of ACTG 384 [17,40], ART regimen was
not found to be a significant predictor of CD4 cell recovery
following ART initiation and thus was not adjusted for during
analysis. Secondary outcomes included an increase of $100 CD4
cells/mm
3 at week 48. In order to maximize power, primary
analyses compared non-Hispanic black persons belonging to the
L2 major haplogroup with all other non-Hispanic blacks. We also
explored differences between L2 and other individual major
haplogroups L1 and L3. Analyses were performed using STATA/
SE 10.1 (StataCorp, College Station, TX).
Results
ACTG 384 enrolled a total of 980 participants, 35% of whom
were self-identified non-Hispanic black race/ethnicity [40]. Of
these, 623 (64%) underwent comprehensive immunophenotyping;
39% of non-Hispanic black race/ethnicity [17]. For initial
mtDNA analyses, 423 participants (126 [30%] non-Hispanic
black) had mtDNA sequencing that passed all genotyping quality
filters, HIV RNA ,400 copies/mL at week 48, and CD4 cell
counts available [39]. Analyses presented here include 104 of these
126 non-Hispanic black participants with available T cell
activation data. Baseline demographics, T cell immunologic
assessments, and randomized ART for these subjects are shown
in Table 1. The median age was 37 years (range 17, 72). Median
baseline CD4 count was 283 cells/mm
3 (interquartile range [IQR]
111, 453); log10 HIV-1 copies/mL was 4.8 (IQR 4.1, 5.4), and
percentage activated CD4 and CD8 cells were 15 (IQR 8, 29) and
45 (IQR 33, 58), respectively. Baseline naı ¨ve-to-memory cell ratio
was available for 91 (88%) subjects, with a median of 0.47 (IQR
0.19, 0.87) among these. CD4 cells correlated with percentage
activated CD4 cells at baseline (rho=20.68; p,0.001) and week
48 (20.53; p,0.001).
Haplogroup distributions (including subhaplogroups) are shown
in Table 2. Major African haplogroups included L1 (N=25
[24%]), L2 (N=31 [30%]), and L3 (32 [31%]). Non-African
haplogroups were observed in 14 (13%) individuals included in
analyses of non-L2 comparison groups. Secondary analyses limited
to persons having African haplogroups yielded similar results (data
not shown). Baseline age, absolute CD4 count, and plasma HIV
RNA were not statistically different between haplogroup L2
individuals and others (Table 1). Randomized NRTIs did not
differ statistically by haplogroup (p=0.20), but L2 individuals
randomized to didanosine plus stavudine tended to be randomized
to the efavirenz arm more often than non-L2 individuals
(p=0.06).
When comparing mtDNA haplogroup L2 with all other
haplogroups (Table 1), baseline median percentage activated
(CD38+/HLA-DR+) CD4 cells was significantly lower (12% [IQR
6, 22] vs. 17% [8,32]; p=0.03) in persons belonging to the L2
haplogroup. Median absolute activated CD4 cells was lower (25
[15,40] vs. 34 [17,51] cells/mm
3; p=0.11), but was not
statistically different. Median percentage activated CD8 cells also
tended to be lower (41% [26,54] vs. 47% [35,59]; p=0.06). After
48 weeks of ART, median CD4 cells was not statistically different
in the L2 versus non-L2 haplogroups (399 [IQR 168, 670] vs. 472
[292, 732]; p=0.13; Table 3). However, the median change from
baseline was significantly less among L2 versus non-L2 hap-
logroups (+95 [23, +182] cells vs. +178 [+105, +312]; p=0.002;
Figure 1A). Similarly, although 48 week percentage activated CD4
cells did not differ (7% [4,11] vs. 6% [4,9]; p=0.57), the median
change in percentage activated CD4 cells was significantly less in
the L2 compared with the non-L2 haplogroups (24% [28, 22]
vs. 211% [226, 24]; p=0.01; Figure 1B). Correlations between
CD4 cells and percentage activated CD4 cells at baseline and
week 48 were similar among L2 and non-L2 haplogroups (data not
shown).
Among other T cell measures, median naı ¨ve CD4 cells
(p=0.06) and absolute CD8 cell counts (p=0.07) at 48 weeks
both tended to be lower among individuals belonging to the L2
haplogroup (Table 3). Median week 48 increases in naı ¨ve CD4
cells also tended to be lower (+43 [+20, +80] vs. +87 [+31, +171];
p=0.06) among haplogroup L2 individuals, as were decreases in
activated CD8 cells (217% [233, 210]; 227 [233, 217];
p=0.09), but these differences were not statistically significant. As
observed in our earlier study, [39] persons in this sub-analysis
belonging to haplogroup L2 were significantly less likely to have an
increase of $100 CD4 cells over the first 48 weeks of suppressive
ART compared to non-L2 individuals (42% vs. 75%; p=0.002).
In separate multivariate models, associations between mtDNA
haplogroup L2 and baseline (pre-ART) and 48-week changes in
percentage activated CD4 cells were assessed with adjustment for
baseline age, absolute CD4 count, HIV RNA, and naı ¨ve-to-
memory CD4 cell ratio. [17] In both models, baseline CD4 count
was strongly associated with percentage activated CD4 cells
(p,0.001; Table 4). Haplogroup L2 was also associated with lower
baseline (b=26.7 [95% CI 212.8, 20.50]; p=0.035) and
smaller 48-week change (b=7.5 [1.6,13.5]; p=0.013) in percent-
age activated CD4 cells.
Discussion
This analysis expands a previous study of mitochondrial
genomic predictors of CD4 cell recovery in ACTG Study 384
[39]. Differences in T cell subsets and activation markers were
observed within the African mtDNA haplogroup that also
demonstrated impaired CD4 cell recovery despite suppressed
HIV RNA after 48 weeks on ART. The most notable differences
included lower CD4 cell activation at baseline despite similar
absolute CD4 counts and HIV RNA, and less decrease in
percentage activated CD4 cells together with a less robust increase
in absolute CD4 cells after 48 weeks of ART (as was previously
reported [39]). There were also several intriguing trends- including
in naı ¨ve CD4 cell populations, and absolute and activated CD8
cell subsets- that did not reach statistical significance in this small
sample but deserve additional study. Although replication in larger
studies and mechanistic validation are needed to confirm these
findings, we interpret these results as suggesting that mtDNA
variation among these non-Hispanic black clinical trial partici-
pants influenced the magnitude of CD4 cell recovery in the first
year after ART by modulating T cell activation through as-yet-
unknown mechanisms. This modulation was independent of other
baseline predictors of short-term CD4 recovery, including age,
CD4 count, and naı ¨ve-to-memory CD4 cell ratio.
The role of the mitochondrion as an apoptotic regulator is well
recognized, and its specific relevance in T cells during HIV-
infection has been studied [49]. In a recent study, peripheral blood
mononuclear cells (PBMCs) from HIV-infected long-term non-
progressors demonstrated less mitochondrial dysfunction and
mitochondria-mediated apoptosis than typical progressors [50].
Studies have also observed reduced mtDNA quantity in PBMCs
from ART-naı ¨ve, HIV-infected compared with HIV-negative
individuals [37,51]. One study reported decreased mtDNA that
mtDNA Variation and T Cell Activation in HIV
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untreated men [36]. Another found decreased mitochondrial
membrane potential and increased apoptosis in PBMCs from
HIV-infected, ART-naive compared with uninfected subjects [52–
53]. These measures correlated with each other, and lower
mitochondrial membrane potential correlated with lower CD4 T
cell counts. In black South Africans [54], total T cell mitochon-
drial depolarization and CD4 T cell apoptosis were increased in
ART-naive compared with treated subjects, and a positive
correlation between these parameters was observed among treated
subjects, suggesting relationships between mitochondrial function
and T cell apoptosis in patients. Finally, recent work from one
group has characterized mechanisms by which mitochondria
might regulate activation in Jurkat T cell lines in the absence of
HIV infection [55–56].Taken together, these data strongly suggest
that adverse mitochondrial phenotypes prior to ART can
contribute to peripheral T cell activation and apoptosis. Published
data on the direct effects of mtDNA variation on cellular apoptosis
are still limited, but include a murine model of mtDNA depletion
[57], and a small study of patients with mtDNA tRNA point
mutations showing an increase in apoptotic muscle fibers (by
TUNEL staining) [58]. An in vitro study in fibroblasts demonstrat-
ed massive ROS-induced apoptosis in the presence of a mtDNA
point mutation [59].
Based on this emerging literature and our results, one could
speculate regarding several possible mechanisms by which mtDNA
variants (in this case, those specifically marking the L2 haplogroup)
might influence CD4 cell recovery. First, T cells harboring specific
L2-associated mtDNA variants may have differential ability to
become and/or remain activated in the presence of antigenic
stimulation. Second, mtDNA variation could lead to differential
susceptibility to cell death (via the intrinsic apoptotic pathway) in
the setting of chronic T cell activation prior to suppression of HIV
replication with ART. This could lead to a lower percentage of
activated T cells prior to starting ART, as was observed here. We
also observed a less robust decrease in percentage activated CD4
(and to a lesser extent, CD8) cells during the first 48 weeks of
ART. If a greater proportion of activated cells progress to
apoptotic cell death among persons with haplogroup L2, this could
explain a less robust gain in absolute CD4 cells over the same time
period. This less robust CD4 cell increase may also be related to
fewer numbers of naı ¨ve CD4 cells- an important component of
CD4 recovery after suppression of viral replication in this
population [17,22]- both at baseline and after 48 weeks of ART.
CD4 cell activation has been associated with CD4 cell recovery
[15–16]. In the overall immunologic analysis of this population
[17], there was no correlation between baseline CD4 cell
activation and CD4 recovery on ART, but higher CD4 and
CD8 activation at week 48 correlated with CD4 recovery at week
48. Although the direction of associations were similar in our
subgroup, we did not observe significant correlations between 48-
week CD4 or CD8 activation and CD4 recovery (data not shown),
Table 1. Baseline demographic data, T cell parameters, HIV RNA, and ART randomization arms among the black, non-Hispanic
ACTG 384 population with baseline CD4 activation markers and 48 week HIV RNA ,400 copies/mL, total and by African L2 and
non-L2 mtDNA haplogroups.
Parameter Total (N=104) L2 (N=31) Non-L2 (N=73) p-value
a
Age (years) 37 (32, 46) 35 (31, 43) 39 (32, 46) 0.44
Female sex, N (%) 29 (28) 6 (19) 23 (32) 0.24
CD4+ (cells/mm
3) 283 (111, 453) 299 (117, 469) 280 (105, 420) 0.63
Naı ¨ve CD4+ (cells/mm
3)[ N=9 5 ]
b 78 (14, 168) 60 (16, 139) 86 (14, 186) 0.47
Memory CD4+ (cells/mm
3)[ N=9 1 ]
b 154 (53, 238) 154 (97, 352) 154 (41, 217) 0.37
Naı ¨ve/memory CD4+ cell [N=91]
b 0.47 (0.19, 0.87) 0.41 (0.13, 0.72) 0.48 (0.22, 1.00) 0.32
CD4+ CD38+/DR+ (cells) [N=95]
b 31 (15, 46) 25 (15, 40) 34 (17, 51) 0.11
CD4+ CD38+/DR+ (%) 15 (8, 29) 12 (6, 22) 17 (8, 32) 0.03
CD8+ (cells/mm
3) 777 (471, 1212) 907 (436, 1349) 775 (481, 1101) 0.80
CD8+ CD38+/DR+ (cells) [N=95]
b 315 (183, 548) 301 (137, 521) 343 (221, 548) 0.34
CD8+ CD38+/DR+ (%) 45 (33, 58) 41 (26, 54) 47 (35, 59) 0.06
HIV RNA 4.8 (4.1, 5.4) 4.8 (4.1, 5.3) 4.8 (4.0, 5.4) 0.79
Randomized ART, N (%)
ZDV+3TC
c 56 (54) 20 (65) 36 (49) 0.20
NFV 17 (30) 6 (30) 11 (31)
EFV 16 (29) 5 (25) 11 (31) 0.88
NFV+EFV 23 (41) 9 (45) 14 (39)
ddI+d4T
c 48 (46) 11 (35) 37 (51) 0.20
NFV 13 (27) 4 (36) 9 (24)
EFV 16 (33) 6 (55) 10 (29) 0.06
NFV+EFV 19 (40) 1 (9) 18 (49)
Data are median (IQR) except where noted.
aWilcoxon ranksum, Fisher’s exact, or Pearson Chi
2 tests, L2 vs. non-L2;
bN with available baseline data shown;
cp-values for NRTI backbone comparison shown.
doi:10.1371/journal.pone.0043803.t001
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Haplogroup/Subhaplogroup- N (%)
a
Total non-Hispanic black with mtDNA
sequence data (N=126) [39]
Non-Hispanic black with mtDNA sequence and
baseline CD4+ activation data (N=104)
African Haplogroups
L1 31 (25) 25 (24)
L1a 7 (6) 4 (4)
L1b 10 (8) 9 (9)
L1c 14 (11) 12 (12)
L1/L2 2 (2) 2 (2)
L2 40 (32) 31 (30)
L2a 25 (20) 22 (21)
L2b 15 (12) 9 (9)
L3 36 (29)
b 32 (31)
b
L3b 12 (10) 11 (11)
L3e 8 (6) 7 (7)
Non-African Haplogroups
A 4 (3) 3 (3)
H2 4 (3) 4 (4)
Others
c 9 (7) 7 (7)
aTotals may not =100% due to rounding;
bTotal includes haplogroup L3, not sub-haplogrouped;
cIncludes haplogroups H, I, J1, T1, T2b, U6, U9 (N#2 each).
doi:10.1371/journal.pone.0043803.t002
Table 3. T cell parameters at 48 weeks and 48 week changes among the black, non-Hispanic ACTG 384 population with baseline
CD4 activation markers and 48 week HIV RNA ,400 copies/mL, total and by African L2 and non-L2 mtDNA haplogroups.
Parameter
Total non-Hispanic
black (N=104) L2 (N=31) Non-L2 (N=73) p-value
a
Week 48
CD4+ (cells/mm
3) 460 (230, 711) 399 (168, 670) 472 (292, 732) 0.13
Naı ¨ve CD4+ (cells/mm
3)[ N=9 8 ]
b 148 (70, 323) 96 (48, 253) 165 (79, 346) 0.06
Memory CD4+ (cells/mm
3)[ N=9 8 ]
b 247 (133, 326) 228 (113, 359) 251 (134, 317) 0.89
CD4+ CD38+/DR+ (cells) [N=97]
b 24 (15, 43) 20 (12, 37) 24 (17, 44) 0.17
CD4+ CD38+/DR+ (%) [N=97]
b 6 (4, 10) 7 (4, 11) 6 (4, 9) 0.57
CD8+ (cells/mm3) 812 (554, 1031) 726 (470–914) 855 (575, 1072) 0.07
CD8+ CD38+/DR+ (cells) [N=99]
b 127 (88, 252) 115 (90, 182) 141 (88, 273) 0.34
CD8+ CD38+/DR+ (%) [N=112]
b 21 (13, 29) 20 (14, 28) 21 (11, 30) 0.87
Week 48-Week 0
CD4+ change (cells/mm
3) +135 (+79, +271) +95 (23, +182) +178 (+105,+312) 0.002
N (%) with $100 CD4 cell increase 68 (65) 13 (42) 55 (75) 0.002
Naı ¨ve CD4+ change (cells) [N=90]
b +74 (+29, +161) +43 (+20, +80) +87 (+31, +171) 0.06
Memory CD4+ change (cells) [N=86]
b +82 (+30, +135) +50 (+15, +125) +104 (+35, +139) 0.11
CD4+ CD38+/DR+ change (cells) [N=89]
b 22.3 (218, +10) 24.5 (211.8, +13.7) 22.3 (223.6, +7.5) 0.37
CD4+ CD38+/DR+ change (%) [N=97]
b 28( 222, 23) 24( 28, 22) 211 (226, 24) 0.01
CD8+ change (cells/mm3) 267 (2320, +223) 2148 (2540, +116) 261 (2255, +260) 0.17
CD8+ CD38+/DR+ change (cells) [N=90]
b 2188 (2324, 251) 2143 (2307, 248) 2204 (2333, 260) 0.46
CD8+ CD38+/DR+ change (%) [N=99]
b 226 (233, 213) 217 (233, 210) 227 (233, 217) 0.09
Data are median (IQR) except where noted.
aWilcoxon ranksum, Fisher’s exact, or Pearson Chi
2 tests, L2 vs. non-L2;
bN with available data shown.
doi:10.1371/journal.pone.0043803.t003
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cells were strongly correlated with percentage activated CD4 cells
at both time points.
A recent analysis using data from several U.S. cohorts reported
associations between European haplogroups and increased prev-
alence of pre-ART progression to AIDS and/or CD4 count
,200 cells/mm
3 among Caucasians [38]. These findings are also
consistent with a role for mtDNA variation in CD4 T cell
dynamics. Another study did not find cross-sectional associations
between mtDNA haplogroups and current CD4 counts or viral
load among a population of predominantly ART-treated HIV-
infected Italians [60]. The present study is, to our knowledge, the
first to assess relationships between ex vivo measures of T cell
activation and mitochondrial genomic variation in a population
with longitudinal data from before and after ART.
Limitations of our data include a small sample size which may
have impaired our ability to detect less robust associations. We
elected to use self-identified race/ethnicity to define our analysis
group instead of genetic ancestry. Secondary analyses that
included only non-Hispanic black individuals with an African L
haplogroup yielded similar results (data not shown). Because of the
focused nature of these analyses, results are not generalizable to
other racial/ethnic groups. We defined virologic suppression as
HIV RNA ,400 copies/mL; it is possible that lower levels of viral
replication influenced T cell activation in these subjects. However,
plasma viral load at week 48 (median [IQR] 1.38 [1.23–1.53]
log10 copies/mL) was not correlated with either CD4 or CD8
activation at week 48 or 48-week changes in activation (data not
shown). Additionally, in a secondary analysis of 89 (86%) persons
with 48-week HIV RNA ,50 copies/mL, results were also similar
(data not shown). All subjects included in these analyses received
older NRTI combinations: stavudine plus didanosine, or zidovu-
dine plus lamivudine. Given the lack of association of CD4 cell
recovery with study arm in prior analyses of this population
[17,22,40–41], we did not include ART in adjusted models, and
do not believe observed relationships between mtDNA haplogroup
and T cell activation markers are explained by NRTI mitochon-
drial toxicity, per se. Studies using data from cohorts of subjects
exposed to newer NRTIs will be necessary to confirm that
relationships persist and are of similar magnitude in this setting.
Less robust CD4 cell recovery on ART has been associated with
HIV-related disease progression [2,4], and with incidence of non-
AIDS-defining cancers in a cohort study that included some
ACTG 384 participants [61]. Our analyses did not include these
outcome data, thus we cannot determine whether less robust
decreases in CD4 cell activation markers and/or CD4 cell
increases observed with the African L2 haplogroup over the first
48 weeks of suppressive ART impacted long-term clinical
Figure 1. Scatter plots of 48 week changes in CD4 cells (Panel A), and percentage activated (CD38+/HLA-DR+) CD4 cells (Panel B).
Haplogroup L2 individuals had a significantly lower median increase in CD4 cells and a lower decrease in percentage activated CD4 cells. Unadjusted
p-values by Wilcoxon ranksum test shown. x-lines = median; dashed lines=25
th and 75
th percentiles.
doi:10.1371/journal.pone.0043803.g001
Table 4. Multivariate models of associations between baseline covariates, haplogroup L2, and percentage CD4 cell activation.
Model 1: Baseline % activated CD4 cells
(N=91)
Model 2: 48 week change in % activated CD4 cells
(N=85)
Covariates b (95% CI) p-value b (95% CI) p-value
Age (per year increase) 20.02 (20.29, +0.25) 0.88 +0.10 (20.15, +0.36) 0.42
Baseline plasma HIV RNA (per log10 copies/mL increase) +2.04 (21.53, +5.61) 0.26 22.11 (25.46, +1.23) 0.21
Naı ¨ve-to-memory CD4 cell ratio (per unit increase) 20.46 (21.40, +0.48) 0.33 +0.24 (20.62, +1.10) 0.58
Baseline CD4 cells (per 10 cell increase) 20.40 (20.54, 20.25) ,0.001 +0.27 (+0.13, +0.40) ,0.001
Haplogroup L2 (vs. others) 26.67 (212.84, 20.50) 0.035 +7.54 (+1.62, +13.46) 0.013
doi:10.1371/journal.pone.0043803.t004
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variation may influence T cell activation, we do not have direct
functional measures of mitochondrial oxidative phosphorylation or
apoptosis in these subjects to provide additional data on potential
mechanisms. Future studies will include such measures.
In summary, we report what is to our knowledge the first
association between mtDNA variation and measures of T cell
activation in an HIV infected population. The careful data and
specimen collection as part of a prospective clinical trial is
a strength of these analyses. Replication of these results in
independent clinical trial datasets is needed, ideally including
African populations where the L2 haplogroup is prevalent. Larger
studies may also allow for more specific assessment of mtDNA
subhaplogroups and/or SNPs associated with even more pro-
nounced differences in CD4 recovery. Mechanistic studies of
mitochondrial function within T cells are feasible, and will be
necessary to further confirm and characterize relationships
between mtDNA variants and T cell function. Ultimately, an
improved understanding of the role of mitochondria and mtDNA
variation in T cell dynamics could lead to improved decisions
about when and in whom to initiate ART, and to targeted
therapeutic interventions that could augment CD4 recovery and
its health benefits in HIV-infected persons.
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